Key result
Diabetes drives a prothrombotic state via platelet hyperreactivity and hypofibrinolysis, supporting targeted antithrombotic therapy.
Why the study?
Current antithrombotic therapies in diabetes remain largely similar to those for patients without diabetes, leading to high rates of treatment failure and increased bleeding risks.
This review outlines the mechanisms of platelet dysfunction and hypofibrinolysis in diabetes, emphasizing the need for tailored antithrombotic therapies to mitigate the high residual risk of atherothrombotic events.
Answers are grounded in this paper and cite their sources.
Does not support changing antithrombotic regimens in diabetes; leaves open targeted therapies pending prospective trials.
Diabetes is a metabolic condition with a rising global prevalence and is characterised by abnormally high blood glucose levels. Cardiovascular disease (CVD) accounts for the majority of deaths in diabetes and, despite improvements in therapy, mortality and hospitalisations in this cohort remain disproportionally higher compared to individuals with normal glucose metabolism. One mechanism for increased CVD risk is enhanced thrombosis potential, due to altered function of the cellular and acellular arms of coagulation. Different mechanisms have been identified that mediate disordered blood clot formation and breakdown in diabetes, including dysglycaemia, insulin resistance, and metabolic co-morbidities. Collectively, these induce platelet/endothelial dysfunction and impair the fibrinolytic process, thus creating a prothrombotic milieu. Despite these abnormalities, current antithrombotic therapies are largely similar in diabetes compared to those without this condition, which explains the high proportion of patients experiencing treatment failure while also displaying an increased risk of bleeding events. In this narrative review, we aimed to summarise the physiological functioning of haemostasis followed by the pathological effects of diabetes mellitus on platelets and the fibrin network. Moreover, we carefully reviewed the literature to describe the current and future therapeutic targets to lower the thrombosis risk and improve vascular outcomes in diabetes.
No takes yet. Share an insight, caveat, or question.
Safdar et al. (2023) conducted a review in Diabetes mellitus. Antithrombotic therapies was evaluated. Diabetes induces a prothrombotic state via platelet hyperreactivity and hypofibrinolysis, highlighting the need for novel, targeted antithrombotic therapies to reduce cardiovascular risk.
Synapse has enriched 10 related papers. Consider them for comparative context: